U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC) – Marketwatch

Monitor for hypertension and treat as needed. For persistent hypertension, despite use of antihypertensive medications, reduce the dose. Arterial and venous thrombotic events have been observed and can be fatal. Use with caution in patients who …

Leave a Reply

Your email address will not be published. Required fields are marked *